6′-Hydroxy Justicidin B Triggers a Critical Imbalance in Ca2+ Homeostasis and Mitochondrion-Dependent Cell Death in Human Leukemia K562 Cells

Jiaoyang Luo, Jiaan Qin, Yanwei Fu, Shanshan Zhang, Xing‐Guo Zhang, Meihua YangFrontiers in Pharmacology 2018 · DOI

TL;DR

This study investigates the anti-cancer potential of 6'-hydroxy justicidin B (HJB), a compound derived from traditional Chinese medicine, against human leukemia K562 cells. HJB effectively inhibits cancer cell proliferation and induces apoptosis by disrupting calcium homeostasis and mitochondrial function, activating key cell death pathways. Furthermore, HJB exhibits favorable pharmacokinetic properties in rats, suggesting its promise as a novel therapeutic agent for leukemia.

What Problem Does This Paper Address?

The development of effective and less toxic anti-cancer drugs remains a critical challenge in medicine. While targeted therapies have shown promise, issues like drug resistance and severe side effects continue to hinder their widespread application. Traditional Chinese medicine offers a rich source of potential therapeutic compounds, but their mechanisms of action often require detailed investigation. This paper addresses the need to understand the anti-leukemia mechanisms of HJB, a compound isolated from Justicia procumbens, and to evaluate its potential as a novel therapeutic agent, particularly for chronic myeloid leukemia (CML), by examining its effects on K562 cells and its pharmacokinetic profile.

Methods

The researchers employed a multi-faceted approach to investigate HJB's effects:

  • Cell Viability Assay (MTT): To assess HJB's cytotoxic effects on K562 cells and compare it to other cancer cell lines and a standard drug, imatinib (IMA).
  • Apoptosis Detection (Annexin V/PI Staining & Flow Cytometry): To quantify the induction of apoptosis in K562 cells treated with HJB.
  • Mitochondrial Membrane Potential (Δψm) Assay (JC-1 staining & Fluorescence Microscopy): To evaluate the impact of HJB on mitochondrial integrity, a key indicator of apoptosis.
  • Calcium Homeostasis Assay (Fluo 3-AM staining & Fluorescence Microscopy): To measure changes in intracellular calcium levels, which are crucial for cell signaling and apoptosis.
  • Protein Expression Analysis (ELISA & Western Blotting): To determine the expression levels of key proteins involved in calcium regulation (TRPC6, SERCA) and apoptosis (caspase-8, caspase-9, cytochrome c, p53).
  • Pharmacokinetic Study in Rats: An Ultra-High Performance Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (UFLC-ESI-MS/MS) method was developed and validated to quantify HJB in rat plasma, allowing for the determination of key pharmacokinetic parameters like Cmax, Tmax, and t1/2.

Datasets

Not discussed in the paper. The study utilized established cell lines (K562, HepG2, MDA-MB-157, MGC-803, HL60, RAW 264.7) and Wistar rats for in vivo studies.

Key Insights and Ideas

  • HJB as a Potent Leukemia Inhibitor: HJB demonstrates significantly higher cytotoxicity against K562 leukemia cells compared to other cancer cell lines tested, making it a promising candidate for leukemia therapy.
  • Mitochondrial Disruption is Key: HJB's ability to decrease mitochondrial membrane potential (Δψm) is a central mechanism driving apoptosis, highlighting the critical role of mitochondria in HJB's anti-cancer action.
  • Calcium Imbalance as a Trigger: HJB disrupts intracellular calcium homeostasis, leading to increased cytosolic calcium levels. This imbalance is intricately linked to mitochondrial dysfunction and subsequent cell death.
  • Activation of Apoptotic Pathways: HJB treatment leads to the activation of key apoptotic caspases (caspase-8 and caspase-9) and the tumor suppressor protein p53, confirming its role in triggering programmed cell death.
  • Favorable In Vivo Profile: HJB exhibits rapid absorption and a relatively long elimination half-life in rats, suggesting good bioavailability and sustained presence in the body, which are desirable traits for a therapeutic drug.

Key Results

  • HJB significantly inhibited the proliferation of K562 cells, with an IC50 of 15.07 ± 1.01 µM.
  • HJB dose-dependently induced apoptosis in K562 cells, increasing the percentage of apoptotic cells from 4.6% in the control group to 12.89% at the highest concentration tested.
  • HJB treatment led to a significant decrease in mitochondrial membrane potential (Δψm) in K562 cells.
  • Cytosolic calcium levels were significantly increased in HJB-treated K562 cells.
  • The expression of TRPC6, a calcium channel regulator, was significantly increased by HJB.
  • Activities of caspase-8 and caspase-9 were significantly elevated in HJB-treated K562 cells.
  • p53 expression was dose-dependently increased in K562 cells following HJB treatment.
  • In rats, HJB showed rapid absorption (Tmax of 2.67 ± 1.33 h) and a relatively long elimination half-life (t1/2 of 5.53 ± 0.15 h) after oral administration.

Limitations and Future Work

  • In Vivo Efficacy and Toxicity: While pharmacokinetic studies in rats are promising, the paper acknowledges that in vivo efficacy and toxicity of HJB remain to be elucidated in future research.
  • Cytochrome c Release Mechanism: The study observed an increase in cytosolic cytochrome c but noted no significant variation in mitochondrial cytochrome c levels after HJB treatment. Further investigation, possibly involving different time points, is needed to fully elucidate the release mechanism.
  • HL60 Cell Line Observations: While HJB showed promising results in HL60 cells (a different leukemia cell line), the paper notes that the regulation of SERCA and TRPC6 in these cells requires further study.
  • Drug Metabolism: The pharmacokinetic study suggests moderate metabolism in vivo, but a deeper understanding of the specific metabolic pathways would be beneficial.

The authors suggest that HJB's favorable pharmacokinetic characteristics and its demonstrated ability to induce apoptosis through mitochondrial and calcium-mediated pathways make it a promising candidate for further development as a novel therapeutic agent for human leukemia.

Summary updated

Abstract

<i>Justicia procumbens</i> (<i>J. procumbens</i>) is a traditional Chinese herbal medicine which was used for the treatment of fever, pain, and cancer. A compound 6'-hydroxy justicidin B (HJB) isolated from <i>J. procumbens</i> exhibits promising biological properties. However, the mechanism of action and the <i>in vivo</i> behavior of HJB remain to be elucidated. In this study, we investigated the mechanism of action of HJB on human leukemia K562 cells and its pharmacokinetic properties in rats. The results demonstrated that HJB significantly inhibited the proliferation of K562 cells and promoted apoptosis. Besides, HJB resulted in decreased mitochondrial membrane potential deltaPSIm, increased the level of the calcium homeostasis regulator protein TRPC6 and cytosolic calcium. The activity of caspase-8, caspase-9 and the expression of p53 were significantly increased after treatment with HJB. Additionally, HJB has rapid absorption rate and relative long elimination <i>t</i><sub>1/2</sub>, indicating a longer residence time <i>in vivo</i>. The results indicate that HJB inhibited the proliferation of K562 cells and induced apoptosis by affecting the function of mitochondria and calcium homeostasis to activate the p53 signaling pathway. The pharmacokinetic study of HJB suggested it is absorbed well and has moderate metabolism <i>in vivo</i>. These results present HJB as a potential novel alternative to standard human leukemia therapies.
BibTeX
@inproceedings{luo2018hydroxy,
  author = {Jiaoyang Luo and Jiaan Qin and Yanwei Fu and Shanshan Zhang and Xing‐Guo Zhang and Meihua Yang},
  title = {{6′-Hydroxy Justicidin B Triggers a Critical Imbalance in Ca2+ Homeostasis and Mitochondrion-Dependent Cell Death in Human Leukemia K562 Cells}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.00601},
}
Figure